Influence of surgery and postoperative therapy and tumor characteristics on patient prognosis in advanced ovarian carcinomas

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 111, Issue 2, 2003, Pages 189-196

  Von Georgi, Richard ^a   Franke, Folker E ^a   Münstedt, Karsten ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Chemotherapy; Immunohistochemistry; Ovarian cancer; Residual tumor; Surgery

Indexed keywords

ANTIINFECTIVE AGENT; CA 125 ANTIGEN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

EID: 0242365350     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(03)00239-2     Document Type: Article

References (46)

1. Junor E.J., Hole D.J., McNulty L., Mason M., Young J. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br. J. Obstet Gynaecol. 106:1999;1130-1136.
2. Münstedt K., von Georgi R., Zygmunt M., Misselwitz B., Stillger R., Künzel W. Shortcomings and deficits in surgical treatment of gynecological cancers: a German problem only? Gynecol. Oncol. 86:2002;337-343.
3. Michel G., De Iaco P., Castaigne D. Extensive cytoreductive surgery in advanced ovarian carcinoma. Eur. J. Gynaecol Oncol. 18:1987;9-15.
4. Griffiths CT. Surgery at the time of diagnosis of ovarian cancer. Management of ovarian cancer. London: Butterworth; 1986. p. 60.
5. Goldie J.H., Coldman A.J. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63:1979;1727-1733.
6. McGuire W.P., Hoskins W.J., Brady M.F.et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:1996;1-6.
7. du Bois A., Lück H.J., Meier W. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an imterim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. Semin. Oncol. 24(Suppl. 15):1997;44-52.
8. Pfleiderer A. Ovarian cancer. In: Hermanek P, Gospodarowicz MK, Henson DE, Hutter RVP, Sobin LH, editors. Prognostic factors in cancer. New York: Springer; 1995. p. 205-15.
9. Eisenhauer E.A., Gore M., Neijt J.P. Ovarian cancer: should we be managing patients with good and bad prognostic factors in the same manner? Ann. Oncol. 10:1999;9-15.
10. Brinkhuis M., Meijer G.A., Baak J.P.A. An evaluation of prognostic factors in advanced ovarian cancer. Eur. J. Obstet Gynecol. Reprod. Biol. 63:1995;115-124.
11. Eisenhauer E.A., Vermorken J.B., van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann. Oncol. 8:1997;963-968.
12. Silva E.G., Robey-Cafferty S.S., Smith T.L., Gershenson D.M. Ovarian carcinomas with transitional cell carcinoma pattern. Am. J. Clin. Pathol. 93:1990;457-465.
13. Gasparini G., Bonoldi E., Viale G.et al. Prognostic and predictive value of tumor angiogenesis in ovarian carcinomas. Int. J. Cancer. 69:1996;205-211.
14. Buttitta F., Marchetti A., Gadducci A.et al. p53 alterations are predictive of chemoresistance and aggessiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br. J. Cancer. 75:1997;230-235.
15. Petty R., Evans A., Duncan I.et al. Drug resistance in ovarian cancer - the role of p53. Pathol. Oncol. Res. 4:1998;97-102.
16. Ottone F., Miotti S., Bottini C.et al. Relationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines. Br. J. Cancer. 76:1997;77-82.
17. Scambia G., Benedetti-Panici P., Ferrandina G.et al. Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br. J. Cancer. 72:1995;361-366.
18. Felip E., Del Campo J.M., Rubio D.et al. Overexpression of c-erbB-2 in epithelial ovarian cancer. Cancer. 75:1995;2147-2152.
19. Goff B.A., Ries J.A., Els L.P.et al. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second look procedure. Gynecol. Oncol. 70:1998;378-385.
20. Germain I., Tetu B., Brisson J., Monodor M., Cherian M.G. Markers of chemoresistance in ovarian carcinomas: an immunohistochemical study of 86 cases. Int. J. Gynecol. Pathol. 15:1996;54-62.
21. Yokoyama Y., Sato S., Fukushi Y.et al. Significance of multi-drug-resistant proteins in predictiing chemotherapy response and prognosis in epithelial ovarian cancer. J. Obstet Gynaecol. Res. 25:1999;387-394.
22. Baekelandt M.M., Holm R., Nesland J.M.et al. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res. 20:2000;1061-1067.
23. Tropé C. Prognostic factors in ovarian cancer. Cancer Treat. Res. 95:1998;287-352.
24. Rustin G.J., Nelstrop A.E., Bentzen S.M.et al. Use of tumour markers in monitoring the course of ovarian cancer. Ann. Oncol. 10(Suppl 1):1999;21-27.
25. Thomas G.M., Dembo A.J. Integrating radiation therapy into the management of ovarian cancer. Cancer. 71:1993;1710-1718.
26. Russell P, Farnsworth A. Surgical pathology of the ovaries. 2nd ed. Tokyo: Churchill Livingston; 1997.
27. Austin R.M., Norris H.J. Malignant Brenner tumor and transitional cell carcinoma of the ovary: comparison. Int. J. Gynecol. Pathol. 6:1987;29-39.
28. Baak J.P.A., Chan K.K., Stolk J.G., Kenemans P. Prognostic factors in borderline and invasive ovarian tumours of the common epithelial type. Pathol. Res. Pract. 182:1987;755-774.
29. Metzger R., Bohle R.M., Pauls K.et al. Angiotensin-converting enzyme in non-neoplastic kidney diseases. Kidney Int. 56:1999;1442-1454.
30. Remmele W., Stegner H.E. Vorschlag zur einheitlichen Definition eines Immunreaktiven Score (IRS) für den immunhistochemischen Östrogenrezeptor-Nachweis (ER-ICA) im Mammakarzinomgewebe. Pathologe. 8:1987;138-140.
31. Münstedt K., Steen J., Knauf A.G.et al. Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer. 89:2000;1783-1791.
32. Valverde J.J., Martin M., Garcia-Asenjo J.A.et al. Prognostic value of DNA quantification in early epithelial ovarian carcinoma. Obstet. Gynecol. 91:2001;409-416.
33. Kehoe S., Powell J., Wilson S., Woodman C. The influence of the operating surgeons' specialisation on patient survival in ovarian carcinoma. Br. J. Cancer. 70:1994;1014-1017.
34. Nguyen H.N., Averette H.E., Hoskins W.et al. National survey of ovarian carcinoma. Part V. The impact of physician's specialty on patients' survival. Cancer. 72:1993;3663-3670.
35. Eisenkop S.M., Friedman R.L., Wang H.-J. Complete cytoreductive surgery is feasable and maximizes survival in patients with advanced ovarian cancer: a prospective study. Gynecol. Oncol. 69:1998;103-108.
36. van der Burg M.E.L., Henzen-Logmans S.C., Foekens J.A.et al. The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot study. Eur. J. Cancer. 29A:1993;1951-1957.
37. Ozols R.F., Garvin A.J., Costa J.et al. Advanced ovarian cancer. Correlation of histologic grade with response to chemotherapy and survival. Cancer. 45:1980;572-581.
38. O'Brien T.J., Tanimoto H., Konishi I., Gee M. More than 15 years of CA 125: what is known about the antigen. Int. J. Biol. Markers. 13:1998;188-195.
39. Hollingsworth H.C., Steinberg S.M., Silverberg S.G., Merino M.J. Advanced stage transitional cell carcinoma of the ovary. Hum. Pathol. 27:1996;1267-1272.
40. Benchimol S., Fuks A., Jothy S.et al. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell. 57:1989;327-334.
41. Fleuren G.J., Nap M. Carcinoembryonic antigen in primary and metastatic ovarian tumors. Gynecol. Oncol. 30:1988;407-415.
42. Bon G.G., von Mensdorff-Pouilly S., Kenemans P.et al. Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays. Clin. Chem. 43:1997;585-593.
43. Dong Y., Walsh M.D., Cummings M.C.et al. Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. J. Pathol. 183:1997;311-317.
44. Kommoss F., Pfisterer J., Thome M.et al. Steroid receptors in ovarian carcinoma: immunohistochemical determination may lead to new aspects. Gynecol Oncol. 47:1992;317-322.
45. Tokuhashi Y., Kikkawa F., Ishikawa H.et al. Distribution of platinum in human gynecologic tissues and pelvic lymph nodes after administration of cisplatin. Gynecol. Obstet Invest. 44:1997;270-274.
46. Hollingsworth H.C., Kohn E.C., Steinberg S.M.et al. Tumor angiogenesis in advanced stage ovarian carcinoma. Am. J. Pathol. 147:1995;33-41.